Key result
Apixaban reduces stroke and systemic embolism ~37% in subclinical AF, but increases bleeding.
Why the study?
The increasing detection of subclinical atrial fibrillation (SCAF) by devices and uncertainty about stroke risk and anticoagulation benefits motivated evaluation of recent trial data for guideline updates.
Do direct oral anticoagulants (DOACs) reduce the risk of stroke and systemic embolism in patients with subclinical atrial fibrillation?
Do direct oral anticoagulants (DOACs) reduce the risk of stroke and systemic embolism in patients with subclinical atrial fibrillation?
Recent trial data showing a reduction in stroke and systemic embolism with apixaban in subclinical AF suggests current guidelines may need reevaluation for DOAC eligibility.
With the widespread use of cardiac implantable electronic devices and smartwatches, device-detected atrial fibrillation (AF) also referred to as subclinical AF (SCAF) is becoming increasingly common. The incidence of device-detected AF varies between 30% and 60%, depending on the definition and the device used for detection. Multiple studies, such as EMBRACE, CRYSTAL-AF, and FIND-AF, have confirmed higher detection rates of SCAF following prolonged rhythm monitoring using implantable loop recorders or external loop recorders in patients with cryptogenic stroke. The stroke risk associated with SCAF primarily depends on two factors: The baseline CHA2DS2-VASc score and the duration of SCAF episodes. Very-short episodes (< 6 minutes) are likely of uncertain significance, whereas episodes lasting > 24 hours increased the risk of stroke/systemic embolism (SE) more than threefold in the ASSERT study. For episodes lasting between 6 minutes and 24 hours, the stroke risk is lower but varies with the baseline CHA2DS2-VASc score. Previous randomized trials of direct oral anticoagulants (DOACs) in patients with cryptogenic stroke-NAVIGATE-ESUS (with rivaroxaban) and RE-SPECT ESUS (using dabigatran)-failed to demonstrate superiority over aspirin. More recently, two dedicated studies in SCAF with DOACs have been published: NOAH-AFNET 6 (with edoxaban) and ARTESIA (with apixaban). NOAH-AFNET 6 was terminated early for futility due to slow enrollment and lower-than-expected event rates. In contrast, apixaban reduced the risk of stroke and SE by 37% in the ARTESIA study, albeit with increased bleeding. These differing results may be attributed to differences in the DOAC used, trial design, and enrolled patient populations. Current ACC/AHA guidelines recommend oral anticoagulation (OAC) for SCAF episodes lasting > 24 hours and a baseline CHA2DS2-VASc score > 2. For those with episodes lasting between 6 minutes and 24 hours, a higher CHA2DS2-VASc score > 3 points towards a benefit of OAC, while a conservative approach-including control of risk factors (e.g. , hypertension, thyroid dysfunction, alcohol intake) and periodic follow-up is warranted for the rest. However, considering the positive ARTESIA results, a reevaluation may be needed. Patients with high CHA2DS2-VASc score (> 4) and SCAF > 24 hours duration may be ideal candidates for DOAC therapy. Those with prior stroke and vascular disease also have a higher stroke risk in future and may be attractive candidates for OAC too. For those with high bleeding risk, re-evaluation after optimizing modifiable bleeding risk factors (e.g. , concomitant medications, blood pressure control) may help determine eligibility for anticoagulation. Ongoing large-scale DOAC trials will further clarify this contentious issue.
No takes yet. Share an insight, caveat, or question.
Pradhan et al. (2026) conducted a review in Subclinical atrial fibrillation. Direct oral anticoagulants (DOACs) was evaluated. Recent trials indicate apixaban reduces the risk of stroke and systemic embolism by 37% in subclinical atrial fibrillation, though with increased bleeding, prompting potential guideline updates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: